Elevation of Vascular Endothelial Growth Factor-A Serum Levels Following Acute Myocardial Infarction. Evidence for its Origin and Functional Significance

A. Kranz, C. Rau, M. Kochs and J. Waltenberger. Elevation of Vascular Endothelial Growth Factor-A Serum Levels Following Acute Myocardial Infarction. Evidence for its Origin and Functional Significance. Journal of Molecular and Cellular Cardiology (2000) 32, 65–72. Following the onset of acute myoca...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Journal of molecular and cellular cardiology 2000-01, Vol.32 (1), p.65-72
Hauptverfasser: Kranz, Andrea, Rau, Christoph, Kochs, Matthias, Waltenberger, Johannes
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:A. Kranz, C. Rau, M. Kochs and J. Waltenberger. Elevation of Vascular Endothelial Growth Factor-A Serum Levels Following Acute Myocardial Infarction. Evidence for its Origin and Functional Significance. Journal of Molecular and Cellular Cardiology (2000) 32, 65–72. Following the onset of acute myocardial infarction (AMI), a number of serum parameters show well-defined changes reflecting myocardial injury. During the consecutive repair phase, compensatory processes are initiated including the formation of a collateral circulation on the basis of angiogenesis and arteriogenesis. An important angiogenic factor is vascular endothelial growth factor-A (VEGF-A), shown to be upregulated in the ischemic myocardium. It is unclear, however, whether acute myocardial ischemia leads to a detectable elevation of VEGF-A serum concentrations. With the use of an immunoradiometric assay, we measured the levels of VEGF-A in the serum of patients after AMI at defined time intervals, of patients with unstable angina pectoris (UAP) and of healthy individuals. In addition, in a small group of patients with subacute myocardial infarction VEGF-A concentrations were measured in coronary sinus blood. The data are given as median followed by the 25th and 75th percentiles. In the group with AMI serum VEGF-A measured 105 [78; 176] pg/ml on day 1 and 114 pg/ml [72; 163] pg/ml on day 3 after onset of AMI. Serum levels of VEGF-A significantly increased on day 7 after AMI to 189 [119; 373] pg/ml (P=0.0103) and on day 10 to 255 [162; 371] pg/ml (P=0.0007). The VEGF-A serum level in healthy controls and in patients with UAP measured 98 [75; 137] pg/ml and 116 [57; 140] pg/ml, respectively. Serum at day 10 after AMI contained VEGF-A at a biologically relevant concentration capable of stimulating proliferation of endothelial cells. Surprisingly, VEGF-A serum levels were similar in samples taken from the coronary sinus with 61 [43; 83] pg/ml. Therefore the main source for VEGF-A in the blood stream is not the infarcted myocardium. However, the number of platelets, a rich source of VEGF-A, is significantly increased after myocardial infarction, i.e. 284 [252; 363]×109/litre v 220 [177; 250]×109/litre. In conclusion, the time course of VEGF-A elevation following AMI strongly suggests that VEGF-A plays a role as an endogenous activator of coronary collateral formation in the human heart. The most likely source of the elevated VEGF-A are platelets, rather than the infarcted myocardium.
ISSN:0022-2828
1095-8584
DOI:10.1006/jmcc.1999.1062